Related Experiment Video
Updated: Mar 24, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
991
Splenic marginal zone lymphoma: from genetics to management
Luca Arcaini1, Davide Rossi2, Marco Paulli3
1Department of Molecular Medicine, University of Pavia, Pavia, Italy; Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
Blood
|March 19, 2016
Summary
Splenic marginal zone lymphoma (SMZL) is a rare cancer. Diagnosis involves spleen or blood/marrow analysis, with specific genetic markers like NOTCH2 mutations aiding identification.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy affecting the spleen, bone marrow, and blood.
- Lymphomagenesis is linked to antigen stimulation and deregulation of genes like NOTCH2 and KLF2.
- Current diagnostic criteria involve spleen histology or specific blood/bone marrow findings.
Purpose of the Study:
- To summarize the key aspects of splenic marginal zone lymphoma.
- To highlight diagnostic biomarkers and prognostic factors.
- To review current and potential future therapeutic strategies.
Main Methods:
- Review of existing literature on SMZL.
- Analysis of diagnostic criteria including histology, immunophenotype, and genetic markers (e.g., 7q deletion, NOTCH2 mutations).
- Evaluation of treatment outcomes and approaches.
Main Results:
- Deletion of 7q and NOTCH2 mutations are highly specific for SMZL diagnosis.
- SMZL typically has an indolent course (median survival ~10 years), but 30% have poor outcomes.
- Hepatitis C virus (HCV) coinfection can be effectively treated by virus eradication in some patients.
Conclusions:
- SMZL diagnosis relies on a combination of clinical, morphological, immunophenotypic, and genetic features.
- Watch-and-wait is suitable for asymptomatic patients; symptomatic treatment includes splenectomy, rituximab, or chemotherapy.
- Future research should focus on deregulated cellular programs as therapeutic targets and improved prognostication.
